Cannabis-Based Nanolipid Formulations for Pain Management
Pharmaceutics · 11.07.2026 · 18 (7) · 844
DOI: 10.3390/pharmaceutics18070844 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.07.2026. Verfasst von Ana Clara Santiago Bastos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, RN, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Brazilian Innovation Agency, North-Rio-Grandense Foundation for Research and Culture.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Medicinal cannabis has gained increasing attention from both the scientific community and clinical practice, due to the therapeutic potential of its major phytocannabinoids, particularly cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), for pain management. This review compiled and analyzed the available evidence regarding the antinociceptive effects of nanoencapsulated cannabinoids compared to free compounds. The published works have explored some pharmaceutical formulations and administration routes on different acute, chronic and neuropathic pain experimental models. The findings indicated that cannabinoids exhibited promising analgesic effects, while nanoencapsulation could enhance its stability and bioavailability. Despite these advances, the number of reports investigating nanostructured cannabinoid-based systems remains limited, with a predominance of preclinical research. A recurrent lack of structural information and quality control data for such works was also noted. Furthermore, there were not identified any research regarding the nanoencapsulation of full-spectrum cannabis oils or whole cannabis extracts, highlighting a significant gap in the current literature. Overall, nanoencapsulation emerges as a versatile strategy to overcome the intrinsic limitations of cannabinoids and expand its clinical applicability for pain treatment. Nevertheless, further efforts are required to determine standardized methodologies, facilitating the translation of preclinical findings into clinical practice, in order to provide stable, safe, effective and more accessible cannabinoid-based therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, RN, Brazil.
- Institute of Biotechnology, Federal University of Uberlândia, Uberlândia 38405-319, MG, Brazil.
ORCID-Profile: Fernanda Nervo Raffin, Leandro S Ferreira, Lígia Nunes de Morais Ribeiro
Förderung
- National Council for Scientific and Technological Development
- Brazilian Innovation Agency
- North-Rio-Grandense Foundation for Research and Culture
Zitieren
APA
Bastos, A. C. S., Sato, A. O., Oliveira, L. C., Raffin, F. N., Moura, T. F. A. L., Ferreira, L. S., Navarro, M. V., & Ribeiro, L. N. M. (2026). Cannabis-Based Nanolipid Formulations for Pain Management. Pharmaceutics, 18(7), 844. https://doi.org/10.3390/pharmaceutics18070844
Vancouver
Bastos ACS, Sato AO, Oliveira LC, Raffin FN, Moura TFAL, Ferreira LS, et al. Cannabis-Based Nanolipid Formulations for Pain Management. Pharmaceutics. 2026;18(7):844. doi:10.3390/pharmaceutics18070844
BibTeX
@article{Bastos2026,
author = {Bastos, Ana Clara Santiago and Sato, Arissa De Oliveira and Oliveira, Luana Carvalho de and Raffin, Fernanda Nervo and Moura, Túlio F A L and Ferreira, Leandro S and Navarro, Marco V and Ribeiro, Lígia Nunes de Morais},
title = {Cannabis-Based Nanolipid Formulations for Pain Management},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {7},
pages = {844},
doi = {10.3390/pharmaceutics18070844}
}
EUVIMED